ATOS
ATOSSA THERAPEUTICS, INC.
NASDAQ · Healthcare · Biotechnology · US
$2.56
−12.03%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$2.70
From 52W high−83.10%
Volume80139.00
Market cap$25.55M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 19, 2026
Open
$2.70
From 52W high
−83.10%
Volume
80139.00
Market cap
$25.55M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.0x
P/E (TTM)
—
RSI (14)
53.2
MomentumView details →
1D Return
−12.03%
YTD Return
−71.24%
SummaryUpdated Jun 1, 2026
Atossa Therapeutics, Inc. (NASDAQ:ATOS) is a clinical-stage biopharmaceutical company founded in 2008 and headquartered in Seattle, Washington. Originally established as Atossa Genetics Inc., the company rebranded to Atossa Therapeutics in January 2020 to better reflect its focus on therapeutic development. The company has evolved from its initial genetics-focused approach to become a specialized developer of treatments for oncology and infectious diseases, with particular emphasis on breast cancer therapeutics. Atossa went public in November 2012 and currently trades on the NASDAQ exchange.
Similar companies
Latest newsMore news →
Atossa Therapeutics declared a dividend of one stapled contingent value right for each common share outstanding on October 19, 2026, or issued thereafter, entitling holders to 25% of net proceeds from monetization of its first qualifying priority review voucher, subject to a $50 million aggregate cap.11d agoAtossa Therapeutics entered into a securities purchase agreement for a registered direct offering of 1,363,638 shares of common stock and accompanying warrants, with expected net proceeds of approximately $4.1 million.131d ago